Sonnet BioTherapeutics (SONN) Registration Filing summary

Company overview and business model

• Operates as a clinical-stage, oncology-focused biotechnology company with a proprietary FHAB platform for biologic medicines of single- or bi-specific action.

• FHAB technology enables targeted drug delivery and extended activity, with applications in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions.

• Holds a U.S. patent for FHAB technology, aiming to differentiate its biopharmaceutical platform for future drug development.

• Incorporated in Delaware, with principal offices in Princeton, NJ; underwent multiple reverse stock splits and a business combination in 2020.

Financial performance and metrics

• Has incurred recurring losses and negative cash flows from operations since inception, requiring substantial additional financing to continue R&D activities.

• Audit report raises substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; will receive proceeds from any cash exercise of warrants.

• Net proceeds from warrant exercises intended for research and development, clinical trials, working capital, repayment of liabilities, and general corporate purposes.